Let's not forget: The GOLD criteria for COPD are based on post-bronchodilator FEV1

European Respiratory Journal

Volumn 23, Issue 4, 2004, Pages 497-498

  Sterk, P J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; EDITORIAL; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELIABILITY; RESPIRATORY AIRFLOW; SMOOTH MUSCLE RELAXATION; SPIROMETRY;

BRONCHODILATOR AGENTS; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY VENTILATION; SPIROMETRY; VITAL CAPACITY;

EID: 1842585962     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00017104     Document Type: Editorial

References (15)

1. National Institutes of Health, National Heart, Lung and Blood Institute. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Publication number 2701, 2001.
2. National Institutes of Health, National Heart, Lung and Blood Institute. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. Update 2003. www.goldcopd.com
3. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Mùrkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117-1122.
4. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22: 268-273.
5. Donaldson GC, Seemungal TAR, Patel IS, Lloyd-Owen SJ, Wilkinson TMA, Wedzicka JA. Longitudinal changes in nature, severity and frequency of COPD exacerbations. Eur Respir J 2003; 22: 931-936.
6. Vestbo J, Lange P. Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 329-332.
7. Van der Molen T, Willemse BWM, Schokker S, ten Hacken NHT, Postma DS, Juniper EF. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes 2003; 1: 13-23.
8. De Marco R, Accordini S, Cerveri I, etAn international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59: 120-125.
9. Lundbäck B, Lindberg A, Lindström M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-122.
10. Global Strategy for Asthma Management and Prevention. National Institute of Health, National Heart, Lung, and Blood Institute. Revised 2002. www.ginasthma.com
11. Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW, for the ISOLDE study investigators. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-664.
12. Chanez P, Vignola AM, O'Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1529-1534.
13. European Respiratory Society/European Lung Foundation. European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. R. Loddenkemper, G.J. Gibson, Y. Sibille, eds. Sheffield, UK, ERSJ, 2003.
14. Croxton TL, Weinmann GG, Senior RM, Wise RA, Crapo JD, Buist AS. Clinical research in chronic obstructive pulmonary disease: Needs and opportunities. Am J Respir Crit Care Med 2003; 167: 1142-1149.
15. Celli BR, MacNee W and ATS/ERS Committee Members. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (in press).